Introduction
Cancer pharmacotherapy is on the cusp of a paradigm shift. The emergence of a richness of targets and developmental agents has resulted from a convergence of scientific advances. However, maximizing the chances of success and optimizing commercial rewards will require developers to mitigate several key scientific, clinical, regulatory and economic obstacles
Scope
- Overview of the clinical and developmental challenges facing players in the oncology sector
- Expert insight into strategies for improving patient selection and optimizing "go and no-go" decisions in progressing late stage clinical development
- Lifecycle management case studies of key targeted therapy agents
- Strategies to overcome pharmacoeconomic challenges hindering the uptake of targeted treatment
Report Highlights
Targeted treatment (TT) will not entirely replace traditional cytotoxic treatment and the latter will continue to form the cornerstone of cancer treatment. However, the co-administration of TT will allow the optimization of cytotoxic doses and so drive the market for both classes over the coming years
Lifecycle management in the era of TT is becoming increasingly more challenging. The key to future success will be intensified efforts to identify responsive patient populations at an earlier stage of the drug development process
Given the mechanistic differences between small molecules and antibodies a logical approach is to combine these two drug classes. While this is an area of active clinical research, key to the success of this economically challenging approach is to identify the best combination of drugs and the patients that will benefit most from treatment
Reasons to Purchase
- Understand clinical and strategic challenges to the commercialization of targeted treatments
- Assess opportunities and risks for the continued development of innovative developmental treatments
- Adopt knowledge from this report to drive strategic planning decisions in oncology drug development
View Cart
